IN8bio Reports 20.9-Month Median Overall Survival with Brain Cancer Treatment
Key Facts
IN8bio said median overall survival for patients with glioblastoma who received repeated doses of its cell therapy was 20.9 months, compared with 13.2 months for a group that received standard of care. The company said the difference represented an increase of 59%, based on updated data presented at the 2026 Society for Neuro-Oncology meeting. The comparison included patients who received the experimental treatment alongside standard of care, versus a contemporaneous comparison group that received standard of care alone. The company said 7 of 14 patients in the repeated-dose group were still alive after two years, compared with 1 of 10 in the comparison group. This figure shows a difference in outcomes between the groups in the data reported by the company, while the results remain associated with an early clinical stage.
The data also showed median progression-free survival of 13.0 months among those who received repeated doses, compared with 6.6 months in the standard-of-care group. The company estimated the increase in this measure at 97% compared with the contemporaneous group. The measure tracks how long the disease remains without progressing and is separate from median overall survival, which measures how long patients survive. In earlier data presented by the company at the 2026 American Society of Clinical Oncology meeting, median progression-free survival was 13.0 months among patients who received repeated doses, compared with 6.6 months for the standard-of-care-only group. Those data included 17 patients treated with DeltEx DRI alongside standard of care, according to the company.
The comparison in the results also included a historical estimate from a study published in The New England Journal of Medicine, which reported median overall survival of 14.6 months and median progression-free survival of 6.9 months. These are historical figures, separate from the contemporaneous standard-of-care group cited by the company, so it compared the experimental treatment's results with both benchmarks in different contexts. The groups also differed in the rate of complete surgical resection: 43% of patients receiving repeated doses underwent complete resection, compared with 80% of the standard-of-care group. This difference places the survival results in the context of patient characteristics and accompanying treatment, without changing the figures reported by the company. IN8bio said the data cutoff for the analysis was October 30, 2026.
The company said intracranial treatment was generally well tolerated in earlier data presented at the American Society of Clinical Oncology meeting, with no dose-limiting toxicities, cytokine release syndrome or neurotoxicity reported. In announcing the results from the neuro-oncology meeting, the company said it had observed no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, nor any major infections or serious treatment-related events. It added that no treatment-related deaths were reported. IN8bio describes its INB-200 and INB-400 programs as clinical trials evaluating DeltEx DRI, a genetically engineered gamma delta T-cell therapy. According to the company, the treatment is designed to resist the immunosuppressive effects on lymphocytes caused by temozolomide, a chemotherapy used as part of standard care.
IN8bio, which trades under the ticker INAB, closed at $0.82 on November 13, 2026, according to EL7 data. That was the closing price in a session before the results were announced and does not measure the stock's movement after the news. The company linked the results to its clinical program for glioblastoma, while the reported figures remain early-stage trial results. The company cautioned that early-trial results do not guarantee future outcomes. The data cutoff used in the analysis was October 30, 2026.